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AbsTrACT
Objective Anaemia is associated with higher mortality 
among patients with non-stroke cardiovascular conditions; 
less is known regarding the relationship between anaemia 
and mortality among patients with acute ischaemic stroke.
Methods Medical records were abstracted for n=3965 
veterans from 131 Veterans Health Administration facilities 
who were admitted with ischaemic stroke in fiscal year 
2007. Haematocrit values within 24 hours of admission 
were classified as ≤27%, 28%–32%, 33%–37%, 38%–
42%, 43%–47% or ≥48%. Multivariate logistic regression 
was used to examine the relationship between anaemia 
and in-hospital, 30-day, 6-month and 1-year mortality, 
adjusting for age, medical comorbidities, modified Acute 
Physiology and Chronic Health Evaluation-III and stroke 
severity. Impact factors were calculated to standardise 
comparisons between haematocrit tier and other 
covariates.
results Among n=3750 patients included in the analysis, 
the haematocrit values were ≤27% in 2.1% (n=78), 28%–
32% in 6.2% (n=234), 33%–37% in 17.9% (n=670), 38%–
42% in 36.4% (n=1366), 43%–47% in 28.2% (n=1059) 
and ≥48% in 9.1% (n=343). Patients with haematocrit 
≤27%, compared with patients in the 38%–42% range, 
were more likely to have died across all follow-up 
intervals, with statistically significant adjusted ORs (aORs) 
ranging from 2.5 to 3.5. Patients with polycythaemia (ie, 
haematocrit ≥48%) were at increased risk of in-hospital 
mortality (aOR=2.9; 95% CI 1.4 to 6.0), compared 
with patients with mid-range admission haematocrits. 
Pronounced differences between patients receiving and not 
receiving blood transfusion limited our ability to perform a 
propensity analysis. Impact factors in the 1-year mortality 
model were 0.46 (severe anaemia), 0.06 (cancer) and 
0.018 (heart disease).
Conclusions Anaemia is independently associated 
with an increased risk of death throughout the first year 
post stroke; high haematocrit is associated with early 
poststroke mortality. Severe anaemia is associated with 
1-year mortality to a greater degree than cancer or heart 
disease. These data cannot address the question of 
whether interventions targeting anaemia might improve 
patient outcomes.
InTrOduCTIOn
Anaemia is an independent predictor of 
mortality among patients with non-stroke 
cardiovascular conditions, such as myocardial 
infarction (MI) and congestive heart failure 
(CHF).1–3 A relationship between baseline 
haematocrit and increased mortality within 
the acute ischaemic stroke population has 
been reported inconsistently.4–9 Some studies 
have found an independent association 
between anaemia and mortality,5 7 9–11 whereas 
other studies have not confirmed this rela-
tionship.4 6 Increased mortality with higher 
haematocrits has been described as well, 
such that a non-linear, U-shaped relationship 
between haematocrit and poststroke mortality 
may exist.8 10 11
Patients with medically complex acute 
stroke may be especially prone to poor 
outcomes in the presence of low or high 
haematocrit values, either through conditions 
associated with extreme haematocrit levels or 
through pathophysiological consequences 
of haematocrit abnormalities (including 
decreased oxygen delivery, alterations in 
blood viscosity and impaired cerebral auto-
regulation).8 9 12–17 Previous studies exam-
ining the relationship between haematocrit 
and mortality in ischaemic stroke have vari-
ably adjusted for important medical condi-
tions and neurological status that contribute 
to mortality.18 Inability to adjust for the 
burden of medical illness and stroke severity, 
combined with analysing haemoglobin based 
on a dichotomous definition of anaemia, may 
be responsible for the variable association 
between haematocrit and mortality reported 
in the literature. More recently, one study 
controlled for age, comorbidities and isch-
aemic stroke subtype, finding that admission 
haemoglobin values of less than 12.4 g/dL 
(approximately a haemoglobin of 37.2%)19 in 
men were associated with increased mortality 
throughout the first year post stroke.10 The 
authors also noted that further studies were 
necessary to understand the potential role 
of haemoglobin augmentation interventions 
among patients with acute ischaemic stroke 
presenting with anaemia.10
We used data from the Veterans Health 
Administration (VHA) to determine whether 
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an association between baseline haematocrit and 
mortality exists throughout the first year post acute isch-
aemic stroke, and to assess the contribution of low and 
high haematocrit values to mortality during this time 
period, while controlling for burden of medical comor-
bidities and stroke severity. Given that the presence of 
lower measures of red blood cell volume was associated 
with greater mortality in prior work,1 10 we investigated 
whether finer tiers of haematocrit were associated with 
even higher mortality.1 Furthermore, we conducted a 
propensity analysis to understand whether receipt of 
blood transfusion among patients with anaemic isch-
aemic stroke affected postevent outcomes.
MeThOds
Patient population
The VHA Office of Quality Performance and the Veterans 
Affairs (VA) Stroke Quality Enhancement Research Initi-
ative collaborated to conduct the first national VHA 
study of inpatient stroke quality. The study design and 
primary findings are reported elsewhere.20 In brief, VA 
administrative data were used to identify a study popu-
lation of veterans (n=5721) who were admitted to a VA 
Medical Center (VAMC) in fiscal year 2007 (FY07) with 
a primary diagnosis of acute ischaemic stroke. A sample 
of 5000 medical records were selected; these included 
all cases from small-volume centres (≤55 patients) and a 
random sample of 80% of veterans at high-volume facil-
ities (>55 patients in FY07).20 Patients were excluded if 
they were admitted for elective carotid endarterectomy, 
for postacute ischaemic stroke rehabilitation or were 
already admitted for a non-stroke condition when the 
ischaemic stroke occurred, leaving a final sample of 
n=3965 veterans from 131 VAMCs for whom full chart 
reviews were performed.
In our current analyses, patients were also excluded 
when haematocrit laboratory values within 24 hours 
of acute stroke admission were unavailable (n=94), or 
when we found inconsistent death dates (n=6). Addi-
tional exclusions were based on limited sample size and 
included women (n=95) and patients who received intra-
venous tissue plasminogen activator (n=32). The final 
analytic sample included 3750 veterans.
data
Date were collected through retrospective chart review 
of medical records using remote electronic record data 
only (ie, no paper records were used). Chart reviews 
were performed by abstractors from the West Virginia 
Medical Institute who were especially trained for the 
study. Among the 307 data elements, 90% had an inter-
observer agreement ≥70% (please refer to online supple-
mentary 1 for a representative sample of select covari-
ates). Data collected for this study included demographic 
factors, medical comorbidities (eg, medical history, 
Charlson Index),21 stroke severity score (as measured 
by the retrospective National Institutes of Health Stroke 
Scale (NIHSS))22 and admission data (eg, vital signs, 
medication, laboratory tests, active medical conditions). 
Race/ethnicity data were obtained from the VHA’s 
Functional Status and Outcomes Database (FSOD), and 
supplemented by the VHA inpatient/outpatient files and 
the Centers for Medicare and Medicaid (CMS) if race/
ethnicity was missing in the FSOD.
Independent variable
The primary outcome of interest was all-cause mortality, as 
measured from the VA Vital Status File (VSF), containing 
dates of deaths from all VA beneficiaries. Death infor-
mation in the VA VSF originates from a variety of VA 
and non-VA sources (eg, CMS). The VA VSF is relatively 
complete and accurate when compared with information 
contained in the National Death Index.23 We examined 
in-hospital, 30-day, 6-month and 1-year mortality.
Primary dependent variable
The primary dependent variable was haematocrit 
values within 24 hours of hospital admission, prespeci-
fied as an ordinal variable based on prior research (not 
involving the ischaemic stroke population) using cate-
gories of ≤27% (severe anaemia), 28%–32% (moderate 
anaemia), 33%–37% (mild anaemia), 38%–42% 
(mid-range; referent), 43%–47% (mid-range) and ≥48% 
(polycythaemia).2 Haematocrit was not dichotomised 
as anaemia based on the WHO criteria (ie, haemo-
globin <13.7 g/dL in men and <12.6 g/dL in women),19 
given previously reported non-linear associations between 
mortality and anaemia in non-stroke conditions1 2 24 and 
ischaemic stroke.6 9 11 We were unable to characterise the 
type of anaemia (eg, iron deficiency, anaemia of chronic 
disease) with the available data.
Covariates
Potential covariates associated with mortality were 
selected a priori based on prior research.9 17 21 25 26 Demo-
graphic variables, admission laboratory values (eg, platelet 
count), admission vital sign data (eg, oxygen saturation) 
and medical comorbidities were considered.21 In addi-
tion, the modified Acute Physiology and Chronic Health 
Evaluation (APACHE)-III25 (factoring out the contribu-
tion of haematocrit) and NIHSS scores were included.22
statistical analysis
All statistical analyses used SAS V.9.2. We conducted 
bivariate analyses to describe the demographic and clin-
ical characteristics of the study sample across each of the 
six categories of haematocrit, and we assessed differences 
using χ2 tests for categorical variables and analysis of vari-
ance tests for continuous variables.
Multivariate logistic regression models were used 
to examine the association between haematocrit and 
mortality, after adjusting for covariates. A ratio of 10 
outcome events per variable was maintained during 
model construction.27 28 A p value of <0.05 was used to 
demarcate statistical significance. The final multivariate 
logistic regression models included confounders selected 
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Table 2 Haematocrit level and mortality
Admission haematocrit value
P values
Overall 
sample 
(n=3750)
≤27%
(n=78)
28%–32%
(n=234)
33%–37%
(n=670)
38%–42% 
(n=1366)
43%–47%
(n=1059)
≥48%
(n=343)
Mortality (%)
In-hospital 3.6 9.0 6.4 4.6 2.7 2.4 5.3 0.0002
30-day 7.8 21.8 14.5 9.3 7.4 4.9 7.3 <0.0001
90-day 14.5 35.9 31.6 21.5 12.6 8.6 9.6 <0.0001
1-year 18.8 43.6 38.5 26.9 16.9 12.6 10.8 <0.0001
Table 3 Association between haematocrit and mortality
In-hospital mortality 30-day mortality 6-month mortality 1-year mortality*
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Age† 1.63 (1.26 to 2.11) 1.870 (1.56 to 2.25) 1.56 (1.36 to 1.78) 1.47 (1.305 to 1.65)
Haematocrit (%)
≤27 3.46 (1.30 to 9.22) 2.47 (1.20 to 5.05) 2.54 (1.39 to 4.63) 2.58 (1.46 to 4.55)
28–32 1.66 (0.75 to 3.67) 1.37 (0.82 to 2.30) 2.19 (1.49 to 3.23) 2.05 (1.43 to 2.95)
33–37 1.67 (0.94 to 3.00) 0.97 (0.65 to 1.45) 1.42 (1.06 to 1.91) 1.30 (1.00 to 1.70)
38–42 1.00 1.00 1.00 1.00
43–47 1.17 (0.63 to 2.16) 0.83 (0.55 to 1.27) 0.84 (0.61 to 1.15) 0.94 (0.72 to 1.23)
≥48 2.89 (1.39 to 6.00) 1.17 (0.64 to 2.14) 0.84 (0.51 to 1.39) 0.68 (0.43 to 1.07)
Platelet count 10 9  per liter 2.92 (1.00 to 8.50) 3.75 (1.69 to 8.31) 2.63 (1.33 to 5.19) 2.40 (1.26 to 4.56)
Charlson Index 0.97 (0.82 to 1.14) 1.019 (0.91 to 1.14) 1.17 (1.08 to 1.28) 1.21 (1.12 to 1.31)
Modified APACHE-III‡ 1.04 (1.02 to 1.07) 1.04 (1.02 to 1.06) 1.02 (1.01 to 1.04) 1.03 (1.01 to 1.04)
NIHSS 1.13 (1.11 to 1.15) 1.145 (1.12 to 1.16) 1.12 (1.11 to 1.14) 1.11 (1.09 to 1.13)
Atrial fibrillation 1.03 (0.57 to 1.86) 1.13 (0.75 to 1.69) 1.41 (1.04 to 1.92) 1.44 (1.08 to 1.91)
Cancer 2.28 (1.16 to 4.50) 2.06 (1.27 to 3.33) 1.84 (1.27 to 2.67) 1.91 (1.36 to 2.69)
Heart disease§ 1.38 (0.87 to 2.18) 1.43 (1.03 to 1.97) 1.07 (0.84 to 1.37) 1.11 (0.89 to 1.38)
COPD/asthma/bronchitis 0.93 (0.52 to 1.66) 1.23 (0.84 to 1.80) 0.95 (0.71 to 1.28) 0.96 (0.74 to 1.26)
Kidney disease requiring 
dialysis¶
NA 0.80 (0.23 to 2.77) 0.81 (0.33 to 1.99) 0.80 (0.35 to 1.83)
Oxygen saturation <90% 1.30 (0.44 to 3.83) 1.65 (0.72 to 3.82) 1.66 (0.80 to 3.44) 1.25 (0.61 to 2.54)
Pneumonia 1.54 (0.56 to 4.25) 3.12 (1.49 to 6.55) 4.45 (2.27 to 8.90) 4.27 (2.16 to 8.45)
*Mortality model discrimination and calibration: in-hospital (C=0.91; HLGOF=0.97); 30-day (C=0.83; HLGOF=0.82); 6-month (C=0.86; 
HLGOF=0.73); 1-year (C=0.88; HLGOF=0.43).
†Age, in 10-year increments.
‡Modified APACHE-III calculated without haematocrit values.
§Heart disease is a composite of history of coronary heart disease, myocardial infarction, coronary artery bypass graft surgery, percutaneous 
transluminal coronary angioplasty/coronary artery stenting, congestive heart failure, carotid artery stenosis and peripheral artery disease.
¶ORs for kidney disease requiring dialysis could not be generated due to the absence of in-hospital mortality events among patients with this 
comorbidity.
 APACHE-III, Acute Physiology and Chronic Health Evaluation-III; C, C-statistic; COPD, chronic obstructive pulmonary disease; HLGOF, 
Hosmer-Lemeshow goodness of fit; NIHSS, National Institutes of Health Stroke Scale; NA, not available. 
a priori and identified in bivariate analyses as important 
predictors of mortality. The final mortality models 
included age (in 10-year increments), medical history 
of heart disease, cancer, chronic obstructive pulmo-
nary disease (COPD), kidney disease requiring dialysis 
and atrial fibrillation, and admission hypoxia (oxygen 
saturation <90%), pneumonia and thrombocytopaenia 
(platelet count <100 cells/mm3),26 modified APACHE-III 
(as a measure of acute severity of disease), Charlson 
Index (as a measure of chronic disease comorbidity) 
and NIHSS (as a measure of stroke severity). No adjust-
ments were made for multiple comparisons. As missing 
data were rare, imputations were not made for missing 
data. Adjusted ORs (aORs) and 95% CIs are presented. 
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Figure 1 Kaplan-Meier curve demonstrating 1-year survival 
by admission haematocrit for men with ischaemic stroke. 
Tiers of haematocrit include ≤27% (orange) (severe anaemia), 
28%–32% (grey) (moderate anaemia), 33%–37% (red) (mild 
anaemia), 38%–42% (green) (referent), 43%–47% (blue) 
and ≥48% (yellow) (polycythaemia). Severe anaemia was 
associated with the highest mortality, beginning during the 
index ischaemic stroke hospitalisation, whereas moderate 
and mild anaemia were associated with increased mortality 
by 6 months after hospital discharge. Polycythaemia 
was associated with mortality only during the index 
hospitalisation.
For each regression model, discrimination (C-statis-
tics) and calibration (Hosmer-Lemeshow goodness of 
fit (HLGOF)) statistics were calculated to gauge model 
performance and fit, respectively.29 30 Finally, survival 
curves were calculated using the Kaplan-Meier method 
and were compared using log-rank statistics.
Impact factors were calculated to make a standardised 
comparison between each category of haematocrit, 
medical comorbidities and NIHSS, and their contribu-
tion to mortality throughout the first year post stroke 
(online supplementary 2).29 30 To assess the contribution 
of blood transfusions on risk of mortality, a propensity 
analysis was conducted.
resulTs
The mean age of n=3750 veterans in the study was 67.9 
years, and 67% were white. The distribution of haematocrit 
categories at admission (table 1) included approximately 
2% with severe anaemia (haematocrit ≤27%) and 9% with 
polycythaemia (haematocrit ≥48%). The bivariate rela-
tionship between haematocrit levels and demographic, 
clinical characteristics and mortality is shown in tables 1 
and 2.
In multivariate logistic regression analyses, both low and 
high levels of haematocrit were significantly associated 
with mortality. Compared with patients with mid-range 
haematocrit levels (38%–42%), patients with severe 
anaemia (≤27%) had aORs of 2.5–3.5 for mortality across 
all time points; all associations were statistically significant 
(table 3). Patients with mild and moderate anaemia also 
experienced increased mortality for 6-month and 1-year 
outcomes (table 3; figure 1). Mid-range haematocrits of 
43%–47% were not associated with increased mortality. 
Polycythaemia was associated only with in-hospital 
mortality (aOR=2.89; 95% CI 1.39 to 6.00). The C-statis-
tics for the models predicting mortality were excellent 
(C-statistic >0.8 for all models). The HLGOF statistics for 
all models were non-significant (HLGOF >0.05), indi-
cating that model fit was good. The impact factors for 
variables in the 1-year mortality model were as follows: 
severe anaemia (0.46), NIHSS (0.23), history of cancer 
(0.06) and heart disease (0.018) (online supplementary 
2).29
Blood was transfused in n=73 (2.0%) of patients at 
admission; n=57 (78.1%) occurred in patients with 
haematocrits <38% (table 1). Patients receiving a blood 
transfusion were more likely to die during the hospi-
talisation (17.8% vs 3.3%), at 30 days (32.9% vs 7.3%), 
6 months (49.3% vs 13.8%) and 1 year (61.6% vs 18.0%) 
(p<0.0001 for all). In conducting a propensity analysis, 
given the pronounced differences between patients who 
did and those who did not receive blood transfusions, a 
stable propensity model could not be developed.
dIsCussIOn
After adjusting for relevant medical conditions, measures 
of acute severity of disease and burden of chronic medical 
comorbidities, and stroke severity, mild and moderate 
anaemia were only associated with increased 6-month 
and 1-year mortality among men. Severe anaemia was 
associated with increased mortality from hospital admis-
sion throughout the first year post stroke. Furthermore, 
severe anaemia at admission was associated with 1-year 
mortality to a similar degree as stroke severity and to a 
greater degree than a history of either heart disease or 
cancer. Polycythaemia was associated only with in-hospital 
mortality, confirming a U-shaped relationship between 
measures of red blood cell volume and postischaemic 
stroke outcomes.8 10 11
The prevalence of anaemia and the association between 
haematocrit and mortality (all-cause and non-cardiovas-
cular) have been described among those with non-stroke 
conditions.1–3 Increased in-hospital and 30-day postacute 
MI mortality has been reported with worsening degrees 
of anaemia.3 Similarly, among patients ≥65 years of age 
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admitted with CHF, haematocrit ≤27% was associated 
with increased 1-year mortality (HR=1.40; 95% CI 1.02 to 
1.92)2; this association was largely attributed to the burden 
of medical comorbidities, suggesting that anaemia may 
be a marker, rather than a prime driver, of increased 
mortality in this population.1
The prevalence of WHO-defined anaemia among 
patients with ischaemic stroke has ranged from 15% to 
25%; the association between haematocrit and mortality 
has been variably described.4 7–9 11 During an ischaemic 
stroke hospitalisation, admission anaemia has been associ-
ated with the combined endpoint of in-hospital mortality 
and discharge to hospice in those with NIHSS<10 
(aOR=4.14; 95% CI 1.47 to 11.90).9 After adjusting for age, 
sex, medical comorbidities, prior disability, NIHSS and 
stroke subtype (ie, ischaemic or haemorrhagic), anaemia 
has been associated with higher mortality at 1 month 
(aOR=1.90; 95% CI 1.05 to 3.43) and 1 year (aOR=1.72; 
95% CI 1.00 to 2.93).11 Elsewhere, increased 6-month 
poststroke mortality (aOR=4.70; 95% CI 1.1 to 8.2) was 
reported after adjusting for age, Scandinavian Stroke 
Score and a combined variable of heart failure and/
or impaired renal function and/or troponin T>0.01 
01 µg/L.7 Additional studies have noted that admission 
anaemia among patients with first atherosclerosis-re-
lated stroke was associated with higher 3-year mortality 
(aOR=2.22; 95% CI 1.13 to 4.39) after controlling for 
age, coronary artery disease, chronic renal insufficiency 
and hyperlipidaemia.5 Others have found that baseline 
haematocrit was not associated with poststroke mortality; 
rather, a decrease in haematocrit value from baseline was 
associated with increased mortality (aOR=1.12; 95% CI 
1.01 to 1.23; p=0.027).6 More recently, in a sample of 3298 
male patients with ischaemic stroke, after controlling for 
age, prestroke modified Rankin Scale score, comorbidi-
ties, Oxfordshire Community Stroke Project classifica-
tion and prior antithrombotic use, a haemoglobin less 
than 12.4 g/dL (approximately a haemoglobin of 37.2%) 
was associated with increased odds of death throughout 
the first year post stroke.10 In examining poststroke 
mortality among patients presenting with haematocrit 
values corresponding to a haemoglobin less than 12.4 g/
dL (ie, ≤27%, 28%–32% and 33%–37%), we report an 
even greater odds of mortality with the lowest measures 
of red blood cell volume.8 10
Higher haematocrit levels have previously been asso-
ciated with increased stroke risk, especially haematocrits 
>45%.10 31 32 Among patients with first ever stroke, the 
literature reports that women were more likely than men 
to have haematocrits >50% (6.6% vs 2.8%; p<0.0001). 
After adjusting for age, vascular risk factors, chronic 
atrial fibrillation, the presence of total anterior circula-
tion infarction and haematocrit categories, haematocrits 
46%–50% and >50% independently predicted 28-day 
mortality in women, but not men.8 Others reported that 
patients with ischaemic stroke in the highest haemo-
globin quartiles (≥15.3 g/dL in men and ≥14.2 g/dL 
in women) had higher 1-month and 1-year mortality 
rates than patients in the middle quartiles.11 Elsewhere, 
higher inpatient and 1-month mortality was noted among 
patients within the highest quintile (≥15.6 g/dL).10 The 
authors postulated that higher haemoglobin values could 
be seen in dehydration and COPD. In our cohort, admis-
sion creatinine and blood/urea/nitrogen were higher 
than the normal reference range, possibly reflecting 
hypovolaemia at the time of presentation, whereas COPD 
occurred more often in patients with lower haematocrits.
Anaemia may reflect the underlying health status of 
patients with stroke, given the advanced age and burden 
of comorbid illnesses that are seen in patients with stroke 
with anaemia compared with patients with more mid-range 
(38%–47%) haematocrit. Oxygen delivery to the brain is 
optimal at a haematocrit of 40%,33 and mid-range haema-
tocrit has been associated with better stroke outcomes 
(eg, discharge to hospice vs inpatient rehabilitation unit; 
improved 3-month modified Rankin score).4 6 Across 
studies, anaemic poststroke patients with cardiac disease, 
malignancy, renal impairment, older age and worse 
stroke severity had higher mortality.3 5 7 9 11 Similar to these 
studies, we found older age, higher comorbid disease 
burden and worse stroke severity occurred commonly 
among patients with lower haematocrits. Anaemia may 
confer increased mortality risk beyond its association with 
medical illness, perhaps through its influence on cerebral 
perfusion pressure and flow dynamics both to and within 
the ischaemic penumbra.
Based on the current results and the extant literature, 
it seems prudent to evaluate patients with stroke for 
treatable causes of anaemia, and to minimise hospital-ac-
quired anaemia during an acute ischaemia stroke admis-
sion. From the available data, haemoglobin augmentation 
strategies cannot be advocated for poststroke patients 
at this time.34 While haemoglobin augmentation strate-
gies have been associated with favourable outcomes in 
patients with MI and CHF, in patients with chronic kidney 
disease, diabetes and anaemia, darbepoetin alfa adminis-
tration was associated with increased stroke risk (5.0% vs 
2.6%, HR: 1.92; 95% CI 1.38 to 2.68, p<0.001).33 Mathe-
matical modelling data support a transfusion threshold 
of haematocrit <30% among patients with acute isch-
aemic stroke.13 When applying this transfusion threshold 
to our cohort, 180 (4.8%) patients would have received 
a blood transfusion. However, receipt of blood transfu-
sion during a hospitalisation for acute ischaemic stroke 
was neither correlated with improved in-hospital nor 
90-day mortality.35 As there were such pronounced differ-
ences between patients with anaemia who did and did 
not receive blood transfusion, a stable propensity model 
could not be generated.35 Additional work is required 
to evaluate whether interventions that treat anaemia or 
polycythaemia reduce poststroke mortality.
The strengths of our study include the large sample size 
and the ability to control for several important medical 
conditions, stroke severity and admission vital sign data. 
Limitations include an entirely male (veteran) popula-
tion, and the results may not be generalisable to women. 
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Of note, prior studies have found that the prevalence of 
anaemia is similar between men and women, but higher 
haematocrit levels were associated with mortality only 
among women.8 24 Second, we cannot comment on the 
aetiology of anaemia and how causes of anaemia may 
influence outcomes. Few of our patients (0.5% of the 
entire sample) had gastrointestinal or genitourinary 
bleeding; it is therefore likely that most of the anaemia in 
this cohort was not secondary to acute blood loss. Third, 
we can only examine the relationship between admission 
haematocrit and mortality, and not trends in haematocrit 
observed during hospitalisation or after discharge. Studies 
have reported that anaemia acquired during an acute 
ischaemic stroke hospitalisation was more predictive of 
poorer outcomes than baseline haematocrit.6 Fourth, we 
are unable to ascertain the cause of death in our cohort, 
although sepsis, acute organ failure and cancer would 
be expected to account for a higher proportion of death 
among patients with severe anaemia compared with more 
normal haematocrit values. In previous work examining 
death certificate data, we reported that most poststroke 
mortality among patients with and without anaemia 
was attributable to the incident stroke, rather than to 
concomitant medical comorbidities.36 Finally, we cannot 
comment on stroke subtype. One study reported no asso-
ciation between elevated haematocrit and large-vessel 
stroke,36 whereas others found an association between 
intracranial atherosclerosis and stroke.5
Recognising the presence and importance of a 
non-linear, U-shaped association between admission 
haematocrit and all-cause poststroke mortality may have 
implications at both the patient level, regarding eval-
uation and management, as well as at the facility level, 
when understanding risk-adjusted outcomes at discrete 
time points.37 Additional work is required to under-
stand whether intervening on anaemia via haemoglobin 
augmentation strategies (eg, blood transfusion) and poly-
cythaemia improves poststroke trajectories of care.
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